Hepatobiliary and Pancreatic Malignancies

  • Dominique Delbeke
  • Ronald C. Walker


A variety of benign and malignant tumors occur in the liver. The most common benign hepatic tumors are cysts followed by cavernous hemangiomas. Focal nodular hyperplasia and adenomas more often affect women on oral contraceptives, whereas fatty infiltration and regenerating nodules more commonly occur in patients with cirrhosis. Abscesses and angiomyolipomas are uncommon. Among malignant tumors, metastases to the liver from various primaries, often multifocal, occur 20 times more often than primary hepatocellular carcinoma (HCC). Although many tumors may metastasize to the liver, this occurs mainly in colorectal, gastric, pancreatic, lung, and breast carcinoma. Ninety percent of malignant primary hepatic tumors are of epithelial origin and include HCC and cholangiocarcinoma.


Positron Emission Tomography Standard Uptake Value Pancreatic Carcinoma Fine Needle Aspiration Biopsy Gallbladder Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Townsend DW, Beyer T, Bloggett TM. PET/CT scanners: A hardware approach to image fusion. Semin Nucl Med 2003;33:193–204.CrossRefPubMedGoogle Scholar
  2. 2.
    Czernin J (ed). PET/CT: Imaging structure and function. J Nucl Med 2004;45(Suppl 1):1S–103S.Google Scholar
  3. 3.
    Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET) : A meta-analysis. Radiology 2002;224:748–756.CrossRefPubMedGoogle Scholar
  4. 4.
    Bipat S, van Leeuwen MS, Comans EF, Pijl ME, Bossuyt PM, Zwinderman AH, Stoker J. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis – meta-analysis. Radiology 2005;237:1230–1231.CrossRefPubMedGoogle Scholar
  5. 5.
    Wiering B, Ruers TJ, Krabbe PF, Dekker HM, Oyen WJ. Comparison of multiphase CT, FDG-PET and intra-operative ultrasound in patients with colorectal liver metastases selected for surgery. Ann Surg Oncol 2007;14:818–826.CrossRefPubMedGoogle Scholar
  6. 6.
    Oppenheim BE. Liver imaging. In Sandler MP, Coleman RE, Wackers FTJ et al. (eds): Diagnostic Nuclear Medicine. Baltimore, MD:Williams and Wilkins, 1996, pp 749–758.Google Scholar
  7. 7.
    Weber G, Cantero A. Glucose-6-phosphatase activity in normal, precancerous, and neoplastic tissues.Cancer Res 1955;15:105–108.PubMedGoogle Scholar
  8. 8.
    Weber G, Morris HP. Comparative biochemistry of hepatomas. III. Carbohydrate enzymes in liver tumors of different growth rates. Cancer Res 1963;23:987–994.PubMedGoogle Scholar
  9. 9.
    Messa C, Choi Y, Hoh CK, Jacobs EL, Glaspy JA, Rege S, Nitzsche E, Huang SC, Phelps ME, Hawkins RA. Quantification of glucose utilization in liver metastases: parametric imaging of FDG uptake with PET. J Comput Assist Tomogr 1992;16:684–689.CrossRefPubMedGoogle Scholar
  10. 10.
    Torizuka T, Tamaki N, Inokuma T, Magata Y, Sasayama S, Yonekura Y, Tanaka A, Yamaoka Y, Yamamoto K, Konishi J. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995;36:1811–1817.PubMedGoogle Scholar
  11. 11.
    Khan MA, Combs CS, Brunt EM, Lowe VJ, Wolverson MK, Solomon H, Collins BT, Di Bisceglie AM. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 2000;32:792–797.CrossRefPubMedGoogle Scholar
  12. 12.
    Delbeke D, Martin WH, Sandler MP, Chapman WC, Wright JK Jr, Pinson CW. Evaluation of benign vs. malignant hepatic lesions with positron emission tomography.Arch Surg 1998;133:510–515.CrossRefPubMedGoogle Scholar
  13. 13.
    Iwata Y, Shiomi S, Sasaki N, Jomura H, Nishiguchi S, Seki S, Kawabe J, Ochi H. Clinical usefulness of positron emission tomography with fluorine-18-fluorodeoxiglucose in the diagnosis of liver tumors. Ann Nucl Med 2000;14:121–126.CrossRefPubMedGoogle Scholar
  14. 14.
    Trojan J, Schroeder O, Raedle J, Baum RP, Herrmann G, Jacobi V, Zeuzem S. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 1999;94:3314–3319.CrossRefPubMedGoogle Scholar
  15. 15.
    Schroder O, Trojan J, Zeuzem S, Baum RP. Limited value of fluorine-18-fluorodeoxyglucose PET for the differential diagnosis of focal liver lesions in patients with chronic hepatitis C virus infection. Nuklearmedizin 1998;37:279–285.PubMedGoogle Scholar
  16. 16.
    Liangpunsakul S, Agarwal D, Horlander JC, Kieff B, Chalasani N. Positron emission tomography for detecting occult hepatocellular carcinoma in hepatitis C cirrhotics awaiting for liver transplantation. Transplant Proc 2003;35:2995–2997.CrossRefPubMedGoogle Scholar
  17. 17.
    Teefey SA, Hildeboldt CC, Dehdashti F, Siegel BA, Peters MG, Heiken JP, Brown JJ, McFarland EG, Middleton WD, Balfe DM, Ritter JH. Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology 2003;226:533–542.CrossRefPubMedGoogle Scholar
  18. 18.
    Wudel LJ, Delbeke D, Morris D, Rice M, Washington MK, Shyr Y, Pinson CW, Chapman WC. The role of FDG-PET imaging in the evaluation of hepatocellular carcinoma. Amer Surg 2003;69:117–126.Google Scholar
  19. 19.
    Ho CL, Yu SC, Yeung DW.11C-Acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med 2003;44:213–221.PubMedGoogle Scholar
  20. 20.
    Ho CL, Shen S, Young DWC, Cheng TKC. Dual tracer PET/CT in the evaluation of hepatocellular carcinoma. J Nucl Med 2007;48:902–909.CrossRefPubMedGoogle Scholar
  21. 21.
    Talbot JN, Gutman F, Fartoux L, Grange JD, Ganne N, Kerrou K, Grahek D, Montravers F, PouponR, Rosmorduc O.PET/CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine: Preliminary comparison with [(18)F]FDG PET/CT. Eur J Nucl Med Mol Imaging 2006;33:1285–1289.CrossRefPubMedGoogle Scholar
  22. 22.
    Keiding S, Hansen SB, Rasmussen HH, Gee A, Kruse A, Roelsgaard K,Tage-Jensen U, Dahlerup JF. Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography. Hepatology 1998;28:700–706.CrossRefPubMedGoogle Scholar
  23. 23.
    Anderson CA, Rice MH, Pinson CW, Chapman WC, Ravi RS, Delbeke D. FDG PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg 2004;8:90–97.CrossRefPubMedGoogle Scholar
  24. 24.
    Kim YJ, Yun M, Lee WJ, Kim KS, Lee JD. Usefulness of 18F-FDG PET in intrahepatic cholangiocarcinomas. Eur J Nucl Med Mol Imaging 2003;30:1467–1472.CrossRefPubMedGoogle Scholar
  25. 25.
    Moon CM, Bang S, Chung JB, Park SW, Song SY, Yun M, Lee JD. Usefulness of (18)F-fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas. J Gastroenterol Hepatol 2008;23:759–765.CrossRefPubMedGoogle Scholar
  26. 26.
    Corvera CU, Blumgart LH, Akhurst T, DeMatteo RP, D'Angelica M, Fong Y, Jarnagin WR.18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg 2008;206:57–65.CrossRefPubMedGoogle Scholar
  27. 27.
    Drouard F, Delamarre J, Capron JP. Cutaneous seeding of gallbladder cancer after laparoscopic cholecystectomy. N Engl J Med 1991;325:1316.PubMedGoogle Scholar
  28. 28.
    Weiss SM, Wengert PA, Harkavy SE. Incisional recurrence of gallbladder cancer after laparoscopic cholecystectomy. Gastrointest Endosc 1994;40:244–246.CrossRefPubMedGoogle Scholar
  29. 29.
    Hoh CK, Hawkins RA, Glaspy JA, Dahlbom M, Tse NY, Hoffman EJ, Schiepers C, Choi Y, Rege S, Nitzsche E, et al. Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose. J Comput Assist Tomogr 1993;17:582–589.CrossRefPubMedGoogle Scholar
  30. 30.
    Lomis KD, Vitola JV, Delbeke D, Snodgrass SL, Chapman WC, Wright JK, Pinson CW. Recurrent gallbladder carcinoma at laparoscopy port sites diagnosed by PET scan: Implications for primary and radical second operations. Am Sur 1997;63:341–345.Google Scholar
  31. 31.
    Rodríguez-Fernández A, Gómez-Río M, Llamas-Elvira JM, Ortega-Lozano S, Ferrón-Orihuela J, Ramia-Angel J, Mansilla-Roselló A, Martínez-del-Valle M, Ramos-Font C. Positron-emission tomography with fluorine-18-fluoro-2-deoxy-D-glucose for gallbladder cancer diagnosis. Am J Surg 2004;188:171–175.CrossRefPubMedGoogle Scholar
  32. 32.
    Gray B, Van Hazel G, Hope M, Burton M, Moroz P, Anderson J, Gebski V. Randomized trial of Sir-spheres plus chemotherapy vs chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001;12:1711–1720.CrossRefPubMedGoogle Scholar
  33. 33.
    Atassi B, Bangash AK, Bahrani A, Pizzi G,Lewandowski RJ, Ryu RK,Sato KT, Gates VL, Mulcahy MF, Kulik L, Miller F, Yaghmai V,Murthy R, Larson A, Omary RA, Salem R. Multimodality imaging following 90Y radioembolization: A comprehensive review and pictorial essay. Radiographics 2008;28:81–99.CrossRefPubMedGoogle Scholar
  34. 34.
    Kalva SP, Thabet A, Wicky S. Recent advances in transarterial therapy of primary and secondary liver malignancies. Radiographics. 2008;28:101–117.CrossRefPubMedGoogle Scholar
  35. 35.
    Torizuka T, Tamaki N, Inouma T, Magata Y, Yonekura Y, Tanaka A, Yamaoka Y, Yamamoto K, Konishi J. Value of fluorine-18-FDG PET to monitor hepatocellular carcinoma after interventional therapy. J Nucl Med 1994;35:1965–1969.PubMedGoogle Scholar
  36. 36.
    Nagata Y, Yamamoto K, Hiraoka M, Abe M, Takahashi M, Akuta K, Nishimura Y, Jo S, Masunaga S, Kubo S et al. Monitoring liver tumor therapy with [18F]FDG positron emission tomography.J Comput Assist Tomogr 1990;14:370–374.CrossRefPubMedGoogle Scholar
  37. 37.
    Vitola JV, Delbeke D, Meranze SG, Mazer MJ, Pinson CW. Positron emission tomography with F-18-fluorodeoxyglucose to evaluate the results of hepatic chemoembolization. Cancer 1996;78:2216–2222.CrossRefPubMedGoogle Scholar
  38. 38.
    Linamond P, Zimmerman P, Raman SS, Kadell BM, Lu DSK. Interpretation of CT and MRI after radiofrequency ablation of hepatic malignancies. Am J Roentgenol 2003;181:1635–1640.Google Scholar
  39. 39.
    Langenhoff BS, Oyen WJ, Jager GJ, Strijk SP, Wobbes T, Corstens FHM, Ruers TJM. Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: A prospective study. J Clin Oncol 2002;20:4453–4458.CrossRefPubMedGoogle Scholar
  40. 40.
    Anderson GS, Brinkmann F, Soulen MC, Alavi A, Zhuang H. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Clin Nucl Med 2003;28:192–197.CrossRefPubMedGoogle Scholar
  41. 41.
    Ludwig V, Hopper OW, Martin WH, Kikkawa R, Delbeke D. FDG-PET surveillance of hepatic metastases from prostate cancer following radiofrequency ablation-Case report. Am Surg 2003; 69:593–598.Google Scholar
  42. 42.
    Donckier V, Van Laetham JL, Goldman S, Van Gansbeke D, Feron P, Ickx B, Wikler D, Gelin M. Fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases. J Surg Oncol 2003;84:215–223.CrossRefPubMedGoogle Scholar
  43. 43.
    Veit P, Antoch G, Stergar H, Bockisch A,  Forsting M, Kuehl H. Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: Initial results. Eur Radiol 2006;16:80–87.CrossRefPubMedGoogle Scholar
  44. 44.
    Barker DW, Zagoria RJ, Morton KA, Kavanagh PV, Shen P. Evaluation of liver metastases after radiofrequency ablation: Utility of FDG PET and PET/CT. Am J Roentgenol 2005;184:1096–1102.Google Scholar
  45. 45.
    Antoch G, Vogt FM, Veit P, Freudenberg LS, Blechschmid N, Dirsch O, Bockisch A, Forsting M, Debatin JF, Kuehl H. Assessment of liver tissue after radiofrequency ablation: Findings with different imaging procedures. J Nucl Med 2005;46:520–525.PubMedGoogle Scholar
  46. 46.
    Wong CY, Salem R, Raman S, Gates VL, Dworkin HJ. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI. Eur J Nucl Med Mol Imag 2002;29:815–820.CrossRefGoogle Scholar
  47. 47.
    Wong CY, Salem R, Qing F, Wong KT, Barker D, Gates V, Lewandowski R, Hill EA, Dworkin HJ, Nagle C. Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: Comparison of quantitative and visual analysis by 18F-FDG PET. J Nucl Med 2004;45:1892–1897.PubMedGoogle Scholar
  48. 48.
    Vargas R, Nino-Murcia M, Trueblood W, Jeffrey RB Jr. MDCT in Pancreatic adenocarcinoma: prediction of vascular invasion and resectability using a multiphasic technique with curved planar reformations. AJR Am J Roentgenol 2004;182:419–425.PubMedGoogle Scholar
  49. 49.
    DeWitt J, Devereaux B, Chriswell M, McGreevy K, Howard T, Imperiale TF, Ciaccia D, Lane KA, Maglinte D, Kopecky K, LeBlanc J, McHenry L, Madura J,. Aisen A, Cramer H, Cummings O, Sherman S. Comparison of endoscopic ultrasonography and multidetector computed tomography for detecting and staging pancreatic cancer. Ann Intern Med 2004;141:753–763.PubMedGoogle Scholar
  50. 50.
    Johnson PT, Outwater EK. Pancreatic carcinoma versus chronic pancreatitis: dynamic MR imaging. Radiology 1999;212:213–218.PubMedGoogle Scholar
  51. 51.
    Lammer J, Herlinger H, Zalaudek G, Hofler H. Pseudotumorous pancreatitis. Gastrointest Radiol 1995;10:59–67.CrossRefGoogle Scholar
  52. 52.
    Brandt KR, Charboneau JW, Stephens DH, Welch TJ, Goellner JR. CT- and US-guided biopsy of the pancreas. Radiology 1993;187:99–104.PubMedGoogle Scholar
  53. 53.
    Chang KJ, Nguyen P, Erickson RA, Durbin TE, Katz KD. The clinical utility of endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of pancreatic carcinoma. Gastrointest Endosc 1997;45:387–393.CrossRefPubMedGoogle Scholar
  54. 54.
    Delbeke D. Pancreatic tumors: Role of imaging in the diagnosis, staging, decision making and treatment. J Hepato-Biliary-Pancreatic Surg 2004;11:4–10.CrossRefGoogle Scholar
  55. 55.
    Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987;235:1492–1495.CrossRefPubMedGoogle Scholar
  56. 56.
    Monakhov NK, Neistadt EL, Shavlovskil MM, Shvartsman AL, Ne1˘fakh SA. Physiochemical properties and isoenzyme composition of hexokinase from normal and malignant human tissues. J Natl Cancer Inst 1978; 61:27–34.PubMedGoogle Scholar
  57. 57.
    Higashi T, Tamaki N, Honda T, Torizuka T, Kimura T, Inokuma T, Ohshio G, Hosotani R, Imamura M, Konishi J. Expression of glucose transporters in human pancreatic tumors compared with increased F-18 FDG accumulation in PET study. J Nucl Med 1997;38:1337–1344.PubMedGoogle Scholar
  58. 58.
    Reske S, Grillenberger KG, Glatting G, Port M, Hildebrandt M,Gansauge F, Beger H-G. Overexpression of glucose transporter 1 and increased F-18 FDG uptake in pancreatic carcinoma. J Nucl Med 1997;38:1344–1348.PubMedGoogle Scholar
  59. 59.
    Gambir SS, Czernin J, Schimmer J, Silverman D, Coleman RE, Phelps ME. A tabulatedsummary of the FDG PET literature. J Nucl Med 2001;42 (Suppl):1S–93S.Google Scholar
  60. 60.
    Rose DM, Delbeke D, Beauchamp RD, Chapman WC, Sandler MP, Sharp KW, Richards WO, Wright JK, Frexes ME, Pinson CW, Leach SD. 18Fluorodeoxyglucose – positron emission tomography (18FDG – PET) in the management of patients with suspected pancreatic cancer. Ann of Surg 1990;229:729–738.CrossRefGoogle Scholar
  61. 61.
    Wahl RL, Henry CA, Ethrer SP. Serum glucose: effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-D-glucose in rodents with mammary carcinoma. Radiology 1992;183:643–647.PubMedGoogle Scholar
  62. 62.
    Lindholm P, Minn H, Leskinen-Kallio S, Bergman J, Ruotsalainen U, Joensuu H. Influence of the blood glucose concentration on FDG uptake in cancer – a PET study. J Nucl Med 1993;34:1–6.PubMedGoogle Scholar
  63. 63.
    Diederichs CG, Staib L, Glatting G, Beger HG, Reske SN. FDG PET: Elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med 1998;39:1030–1033.PubMedGoogle Scholar
  64. 64.
    Diederichs CG, Staib L, Vogel J, Glasbrenner B,Glatting G, Brambs H-J, Beger H G, Reske SN. Values and limitations of FDG PET with preoperative evaluations of patients with pancreatic masses. Pancreas 2000;20:109–116.CrossRefPubMedGoogle Scholar
  65. 65.
    Stollfuss JC, Glatting G, Friess H, Kocher F, Berger HG, Reske SN. 2-(Fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: Value of quantitative image interpretation. Radiology 1995;195:339–344.PubMedGoogle Scholar
  66. 66.
    Zimny M, Bares R, Faß J, Adam G,Cremerius U, Dohmen B, Klever P, Sabri O, Schumpelick V, Buell U. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med 1997;24:678–682.Google Scholar
  67. 67.
    Ho CL, Dehdashti F, Griffeth LK, Buse PE, Balfe Dennis M, Siegel BA. FDG-PET evaluation of indeterminate pancreatic masses. Comput Assist Tomogr 1996;20:363–369.CrossRefGoogle Scholar
  68. 68.
    Friess H, Langhans J, Ebert M, Beger HG, Stollfuss J, Reske SN, Büchler MW. Diagnosis of pancreatic cancer by 2[F-18]-fluoro-2-deoxy-D-glucose positron emission tomography. Gut 1995;36:771–777.CrossRefPubMedGoogle Scholar
  69. 69.
    Shreve PD. Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease. Eur J Nucl Med 1998;25:259–264.CrossRefPubMedGoogle Scholar
  70. 70.
    van Kouwen M, Jansen JB, van Goor H, de Castro S, Oyen WJ, Drenth JP. FDG-PET is able to detect pancreatic carcinoma in chronic pancreatitis. Eur J Med Mol Imaging 2005;32:399–404.CrossRefGoogle Scholar
  71. 71.
    Sperti C, Bissoli S, Pasquali C, Frison L, Liessi G, Chierichetti F, Pedrazzoli S.18-Fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas. Ann Surg 2007;246:932–939.CrossRefPubMedGoogle Scholar
  72. 72.
    Nakata B, Chung YS, Nishimura S, Nishihara T, Sakurai Y, Sawada T, Okamura T, Kawabe J, Ochi H, Sowa M.18F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic carcinoma. Cancer 1997;79:695–699.CrossRefPubMedGoogle Scholar
  73. 73.
    Zimny M, Fass J, Bares R, Cremerius O, Sabri P, Buechin V, Schumpelick U, Buell M. Fluorodeoxyglucose positron emission tomography and the prognosis of pancreatic carcinoma. Scand J Gastroenterol 2000;35:883–888.CrossRefPubMedGoogle Scholar
  74. 74.
    Sperti C, Pasquali C, Chierichetti F, Ferronato A, Decet G, Pedrazzoli S. 18-Fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma. J Gastrointest Surg 2003;7:953–959.CrossRefPubMedGoogle Scholar
  75. 75.
    Delbeke D, Rose M, Chapman WC, Rose M, Chapman WC, Pinson CW, Wright JK, Beauchamp DR, Leach S. Optimal interpretation of F-18FDG Imaging of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med 1999;40:1784–1792.PubMedGoogle Scholar
  76. 76.
    Frolich A, Diederichs CG, Staib L, Vogel J, Beger HG, Reske SN. Detection of liver metastases from pancreatic cancer using FDG PET. J Nucl Med 1999;40:250–255.Google Scholar
  77. 77.
    Kalady MF, Clary BM, Clark LA, Gottfried M, Rohren EM, Coleman RE,Pappas TN, DS Tyler, Clinical utility of positron emission tomography in the diagnosis and management of periampullary neoplasms. Ann Surg Oncol 2002;9:799–806.CrossRefPubMedGoogle Scholar
  78. 78.
    Whiteford MH, Whiteford HM, Yee LF, Ogunbiyi OA, Dehdashti F,  Siegel BA, Birnbaum EH, Fleshman JW,  Kodner IJ,  Read TE. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum 2000;43:759–767; discussion 767–770.CrossRefPubMedGoogle Scholar
  79. 79.
    Podoloff DA, Ball DW, Ben-Josef E, Benson AB, Cohen SJ, Coleman RE, Delbeke D, Ho M, Ilson DH, Kalemkerian GP, Lee RJ, Loeffler JS, Macapinlac HA, Morgan RJ, Siegel BA, Singhal S, Tyler DS, Wong RJ. NCCN Task Force: Clinical Utility of PET in a Variety of Tumor Types Task Force. J Natl Compr Canc Netw 2009;7 Suppl 2:S1–S23. Google Scholar
  80. 80.
    Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, Coleman E, Wahl R, Paschold JC, Avril N, Einhorn LH, Suh WW, Samson D, Delbeke D, Gorman M, Shields AF. Recommendations for the Use of FDG(fluorine-18, (2-[18F]Fluoro-2-deoxy-D-glucose) positron emission tomography in oncology. J Nucl Med 2008;49:480–508.CrossRefPubMedGoogle Scholar
  81. 81.
    Reske SN, Kotzerke J. FDG-PET for clinical use. Results of the 3rd German interdisciplinary consensus conference, Onko-PET III, 21 July and 19 September 2000. Eur J Nucl Med 2001;28:1707–1723.CrossRefPubMedGoogle Scholar
  82. 82.
    Guthrie JA, Ward J, Robinson PJ. Hilar cholangiocarcinomas: T2-weighted spin-echo and gadolinium-enhanced FLASH MR imaging. Radiology 1996;201:347–351.PubMedGoogle Scholar
  83. 83.
    Hussain SM, Terkivatan T, Zondervan PE, Lanjouw E, de Rave S, Ijzermans JN, de Man RA. Focal nodular hyperplasia : Findings at state-of-the-art MR imaging, US, CT and pathologic analysis. Radiographics 2004;24:3–17. CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of Radiology and Radiological SciencesVanderbilt University Medical CenterNashvilleUSA

Personalised recommendations